PMGC Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELAB research report →
Price Chart
About the company
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists.
- CEO
- Graydon Bensler
- IPO
- 2023
- Employees
- 33
- HQ
- Newport Beach, CA, US
Get TickerSpark's AI analysis on ELAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.49M
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.58
- P/B
- 0.10
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 10.31%
- Op Margin
- -477.02%
- Net Margin
- -522.97%
- ROE
- -118.11%
- ROIC
- -39.73%
Latest fiscal year · YoY change
- Revenue
- $590.08K-76.1%
- Gross Profit
- $74.81K-95.8%
- Op Income
- $-7,376,710
- Net Income
- $-7,708,137-23.4%
- EPS
- $-3787.40+94.3%
- OCF Growth
- -8.1%
- FCF Growth
- -16.3%
- 52W High
- $2671.20
- 52W Low
- $2.58
- 50D MA
- $6.32
- 200D MA
- $70.98
- Beta
- -0.27
- RSI (14)
- 26
- Avg Volume
- 143.14K
No earnings-call transcripts are available for ELAB yet.
- Free Float
- 90.0%
- Shares Outstanding
- 454.38K
- Float Shares
- 408.98K
of shares held by institutions
6 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 81.50K | ▲ 49.91K |
| Morgan Stanley | 53.00K | ▲ 38.00K |
| Vanguard Fiduciary Trust Co | 34.01K | ▲ 34.01K |
| Geode Capital Management, LLC | 24.08K | ▲ 24.08K |
| Citadel Advisors LLC | 20.70K | ▲ 20.70K |
| Vanguard Capital Management LLC | 16.67K | ▲ 16.67K |
| Virtu Financial LLC | 16.61K | ▲ 16.61K |
| Xtx Topco Ltd | 14.15K | ▲ 14.15K |
| Tower Research Capital LLC (Trc) | 2.50K | ▲ 2.38K |
| Ubs Group AG | 2.35K | ▲ 1.05K |
| Ifp Advisors, Inc | 1.00K | ▼ 1.00K |
| Danske Bank A/S | 1 | ▲ 1 |
Held by 5 ETFs
Biggest fund positions in ELAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Parry Jeffrey | other | 75,046 |
| Jun 1, 26 | Kovalyov George | other | 75,046 |
| Jun 1, 26 | Daley Juliana | other | 75,046 |
| Jun 1, 26 | Braeden Lichti | other | 450,277 |
| Nov 13, 23 | Parry Jeffrey | other | 0 |
| Sep 30, 22 | Parry Jeffrey | other | 1 |
| Sep 30, 22 | Parry Jeffrey | other | 4 |
| Nov 13, 23 | Daley Juliana | other | 0 |
| Jun 1, 23 | Daley Juliana | other | 4 |
| Mar 6, 24 | Kovalyov George | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELAB coverage
Recent articles, reports, and earnings notes.
No research on ELAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELAB report →PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
globenewswire.com · Oct 1
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
globenewswire.com · Sep 29
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
globenewswire.com · Sep 18
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
globenewswire.com · Sep 1
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
globenewswire.com · Aug 26
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
globenewswire.com · Aug 25
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
globenewswire.com · Aug 21
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
globenewswire.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.